Assignee
APELLIS PHARMACEUTICALS INC
US·22 granted patents·38 pending applications·90 citations·filing 2013–2025
Top patents by PatentIndex Score
60 records- 0194US10407466B2Methods of selecting compstatin mimeticsAPELLIS PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·12 cites·2 claims
- 0293US11338013B2Combination therapy for C3 inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2017·Granted May 24, 2022·7 cites·19 claims
- 0393US11292815B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 5, 2022·2 cites·11 claims
- 0493US11001610B2Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted May 11, 2021·4 cites·23 claims
- 0593US10875893B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Dec 29, 2020·10 cites·9 claims
- 0693US10308687B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2014·Granted Jun 4, 2019·14 cites·13 claims
- 0793US10035822B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2013·Granted Jul 31, 2018·15 cites·12 claims
- 0892US12290566B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2023·Granted May 6, 2025·2 cites·20 claims
- 0992US11844841B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 19, 2023·4 cites·26 claims
- 1092US11407789B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·2 cites·11 claims
- 1188US11040107B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·9 cites·24 claims
- 1288US10941184B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2019·Granted Mar 9, 2021·3 cites·11 claims
- 1388US2025282823A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1486US11013782B2Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2019·Granted May 25, 2021·1 cites·24 claims
- 1585US11510939B1RNAs for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 29, 2022·1 cites·16 claims
- 1685US2026062448A1Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1783US2024076317A1Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1882US11903994B2Dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2016·Granted Feb 20, 2024·4 cites·10 claims
- 1978US12251395B2RNAS for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Granted Mar 18, 2025·0 cites·7 claims
- 2078US2023091471A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2176US11661441B2Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted May 30, 2023·0 cites·34 claims
- 2276US2023075121A1Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2375US12528836B2Dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2023·Granted Jan 20, 2026·0 cites·10 claims
- 2475US11712460B2Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 1, 2023·0 cites·19 claims
- 2574US2022249663A1Methods and compositions for cancer treatment and treatment selectionAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2674US2024285783A1Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2773US12458695B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2025·Granted Nov 4, 2025·0 cites·30 claims
- 2873US10696718B2Compstatin analogs for treatment of neuropathic painAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Jun 30, 2020·0 cites·3 claims
- 2971US2020325175A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3070US2021107944A1Compstatin analogs for treatment of neuropathic painAPELLIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3168US2023009757A1Combination therapy for c3 inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3267US11291407B2Detection of high risk drusenAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 5, 2022·0 cites·7 claims
- 3367US2025075209A1Rnas for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3466US2016194359A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3565US2017166610A1Compstatin Analogs for Treatment of Neuropathic PainAPELLIS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3664US2020316163A1Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3764US2024216538A1Genomic editing of complementAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3864US2025297287A1Compositions and methods for genome editing the neonatal fc receptorAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3964US2020155675A1Methods and compositions for cancer treatment and treatment selectionAPELLIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4064US2025002910A1Treatment of complement-mediated disordersAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4162US2017283461A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4262US2015150945A1Modifying Macrophage Phenotype for Treatment of DiseaseAPELLIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4361US2024110182A1Genomic editing of complementAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4460US2026069653A1Complement inhibitor dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4560US2019192617A1Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4660US2025000936A1Treatment of geographic atrophyAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4758US2023095695A1Rnas for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4858US2017246298A1Methods and compositions for cancer treatment and treatment selectionAPELLIS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4957US2024360103A1Complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5057US2016067357A1Detection of high risk drusenAPELLIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when APELLIS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →